Results for the ISCHEMIA trials: To intervene or not to intervene?

Reported from the AHA Scientific Sessions 2019 in Philadelphia - USA

At AHA 2019 in Philadelphia - USA, Judith S Hochman presented the results of the ISCHEMIA trial. Mirvat Al Asnag interviews David J Maron and Francesco Costa interviews Gregg W. Stone about the primary results of these trials.

ISCHEMIA - International study of comparative health effectiveness with medical and invasive approaches: primary report of clinical and quality of life outcomes

Watch this interview of Francesco Costa with Gregg W. Stone:

The ISCHEMIA trial is a landmark in recent cardiovascular history. Could you please describe the design of the study and the main results?
After the results of the ISCHEMIA trial in terms of outcomes and quality of life, what is your take-home message and how will your practice change?
How the results of the ISCHEMIA trial will be accepted by the Public, including the Patients and the Media?

Watch the interview of Mirvat Al Asnag with David J Maron:

How does the ISCHEMIA-CKD (Chronic Kidney Disease) trial defer from the ISCHEMIA trial in terms of design?
Do you think the results could be applicable to a wide range of centres which may not be capable of performing low contrast with intracoronary imaging?
Lots of asymptomatic patients are referred to the cath lab for evaluation for transplant: How does the ISCHEMIA trial fit into that population?
The rate of stroke was a little higher in revascularisation in CKD patients: should we be cautious when considering invasive approach with these patients?
Could the lower rate of MIs in the revascularisation arm be due to dual antiplatelet therapy?